1
|
García-González S, Aboul-Hosn Centenero S, Baumann P, Fita-Esteban I, Hernández-Alfaro F, Weyer N. Prospective, multi-centric, international, single-arm, cohort study to assess a synthetic polyamide suture material in oral surgery to close the mucosa - MUCODA study. J Dent 2024; 145:104922. [PMID: 38490322 DOI: 10.1016/j.jdent.2024.104922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 02/27/2024] [Accepted: 03/01/2024] [Indexed: 03/17/2024] Open
Abstract
OBJECTIVES The aim was to collect different clinical parameters systematically and proactively regarding safety, effectiveness, and performance of a nylon monofilament suture under routine clinical practice for oral surgery. METHODS The study design was prospective, bicentric, international, single-armed, and observational. A non-absorbable suture was applied to close the mucosa after different dental surgical interventions. Main objective was the incidence of combined postoperative complications until suture removal. The 95 % Confidence Interval (Agresti-Coull method) was used to prove the non-inferiority with a pre-specified upper margin of 21.9 %. Secondary variables were intraoperative suture handling, patient pain and satisfaction, wound healing, aesthetic appearance, and bacterial contamination. RESULTS 105 patients were enrolled. Complication rate was low (1.9 %), 2 swellings occurred. Pain was present for 1.61 days ± 1.42 after various dental interventions with an average pain level of 20.98 ± 22.60 (VAS). Patients with impacted third molar extraction showed the longest pain duration (6 days) combined with the highest mean pain level of 35.33 ± 30.45 (VAS). Intraoperative suture handling was very good to excellent. Suture removal was done after an average duration of 7.56 ± 2.09 days. Patient's satisfaction was high, and an excellent wound healing was reported by the dentists. Aesthetic appearance only performed in implant patients was rated by oral surgeons with an average of 96.19 ± 3.79 points [min. 80 - max. 100] at 5 months postoperatively. Thread bacterial analysis showed that F. nucleatum was the most present species. CONCLUSIONS Our findings indicate that the non-absorbable, nylon-based monofilament suture used is safe and quite suitable for oral mucosal closure after various dental surgical interventions such as tooth extraction, implant placement and impacted third molar extraction. CLINICAL SIGNIFICANCE This study showed the safe use of a non-absorbable, nylon-based monofilament suture for different oral surgical interventions under daily routine clinical practice.
Collapse
Affiliation(s)
- S García-González
- Department of Oral Surgery, International University of Catalonia, Carrer de Josep Trueta, 08195 Sant Cugat del Vallès, Barcelona, Spain.
| | - S Aboul-Hosn Centenero
- Department of Oral Surgery, International University of Catalonia, Carrer de Josep Trueta, 08195 Sant Cugat del Vallès, Barcelona, Spain
| | - P Baumann
- Department of Medical Scientific Affairs, Aesculap AG, Am Aesculap Platz 78532 Tuttlingen, Germany
| | - I Fita-Esteban
- Department of Medical Scientific Affairs, B. Braun Surgical, S.A.U., Carretera de Terrassa 121 08191 Rubí, Barcelona, Spain
| | - F Hernández-Alfaro
- Department of Oral Surgery, International University of Catalonia, Carrer de Josep Trueta, 08195 Sant Cugat del Vallès, Barcelona, Spain
| | - N Weyer
- Praxisklinik für MKG, Ästhetische und Plastische Chirurgie, Schwerpunkt Implantologie, Fabrikstraße 10/1, 73728 Esslingen am Neckar, Germany
| |
Collapse
|
2
|
Golling M, Breul V, Zielska Z, Baumann P. The 6:1 short stitch SL-WL-ratio: short term closure results of transverse and midline incisions in elective and emergency operations. Hernia 2024; 28:447-456. [PMID: 38285168 PMCID: PMC10997695 DOI: 10.1007/s10029-023-02927-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 10/27/2023] [Indexed: 01/30/2024]
Abstract
AIM To analyze laparotomy closure quality (suture/wound length ratio; SL/WL) and short term complications (surgical site occurrence; SSO) of conventional midline and transverse abdominal incisions in elective and emergency laparotomies with a longterm, absorbent, elastic suture material. METHOD Prospective, monocentric, non-randomized, controlled cohort study on short stitches with a longterm resorbable, elastic suture (poly-4-hydroxybutyrate, [p-4OHB]) aiming at a 6:1 SL/WL-ratio in midline and transverse, primary and secondary laparotomies for elective and emergency surgeries. RESULTS We included 351 patients (♂: 208; ♀: 143) with midline (n = 194), transverse (n = 103), and a combined midline/transverse L-shaped (n = 54) incisions. There was no quality difference in short stitches between elective (n = 296) and emergency (n = 55) operations. Average SL/WL-ratio was significantly higher for midline than transverse incisions (6.62 ± 2.5 vs 4.3 ± 1.51, p < 0.001). Results in the first 150 patients showed a reduced SL/WL-ratio to the following 200 suture closures (SL/WL-ratio: 5.64 ± 2.5 vs 6.1 ± 2.3; p < 0.001). SL/WL-ratio varied insignificantly among the six surgeons participating while results were steadily improving over time. Clinically, superficial surgical site infections (SSI, CDC-A1/2) were encountered in 8%, while 4,3% were related to intraabdominal complications (CDC-A3). An abdominal wall dehiscence (AWD) occurred in 22/351 patients (6,3%)-twice as common in emergency than elective surgery (12,7 vs 5,1%)-necessitating an abdominal revision in 86,3% of cases. CONCLUSION We could show that a short stitch 6:1 SL/WL-ratio with a 2-0 single, ultra-long term, absorbent, elastic suture material can be performed in only 43% of cases (85% > 4:1 SL/WL-ratio), significantly better in midline than transverse incisions. Transverse incisions should preferably be closed in two layers to achieve a sufficient SL/WL-ratio equivalent to the median incision. CLINICAL TRIALS GOV IDENTIFIER NCT01938222.
Collapse
Affiliation(s)
- M Golling
- Diakonieklinikum Schwäbisch Hall, Schwäbisch Hall, Germany.
| | | | - Z Zielska
- Diakonieklinikum Schwäbisch Hall, Schwäbisch Hall, Germany
| | | |
Collapse
|
3
|
Caminer MA, Libbrecht R, Majoe M, Ho DV, Baumann P, Foitzik S. Task-specific odorant receptor expression in worker antennae indicates that sensory filters regulate division of labor in ants. Commun Biol 2023; 6:1004. [PMID: 37783732 PMCID: PMC10545721 DOI: 10.1038/s42003-023-05273-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 08/22/2023] [Indexed: 10/04/2023] Open
Abstract
Division of labor (DOL) is a characteristic trait of insect societies, where tasks are generally performed by specialized individuals. Inside workers focus on brood or nest care, while others take risks by foraging outside. Theory proposes that workers have different thresholds to perform certain tasks when confronted with task-related stimuli, leading to specialization and consequently DOL. Workers are presumed to vary in their response to task-related cues rather than in how they perceive such information. Here, we test the hypothesis that DOL instead stems from workers varying in their efficiency to detect stimuli of specific tasks. We use transcriptomics to measure mRNA expression levels in the antennae and brain of nurses and foragers of the ant Temnothorax longispinosus. We find seven times as many genes to be differentially expressed between behavioral phenotypes in the antennae compared to the brain. Moreover, half of all odorant receptors are differentially expressed, with an overrepresentation of the 9-exon gene family upregulated in the antennae of nurses. Nurses and foragers thus apparently differ in the perception of their olfactory environment and task-related signals. Our study supports the hypothesis that antennal sensory filters predispose workers to specialize in specific tasks.
Collapse
Affiliation(s)
- Marcel A Caminer
- Institute of Organismic and Molecular Evolution, Johannes Gutenberg University Mainz, Mainz, Germany.
| | - Romain Libbrecht
- Institute of Organismic and Molecular Evolution, Johannes Gutenberg University Mainz, Mainz, Germany
- Institut de Recherche sur la Biologie de l'Insecte, UMR 7261, CNRS, University of Tours, Tours, France
| | - Megha Majoe
- Institute of Organismic and Molecular Evolution, Johannes Gutenberg University Mainz, Mainz, Germany
| | - David V Ho
- Institute of Developmental and Neurobiology, Johannes Gutenberg University Mainz, Mainz, Germany
| | - Peter Baumann
- Institute of Developmental and Neurobiology, Johannes Gutenberg University Mainz, Mainz, Germany
- Institute of Molecular Biology, Mainz, Germany
| | - Susanne Foitzik
- Institute of Organismic and Molecular Evolution, Johannes Gutenberg University Mainz, Mainz, Germany
| |
Collapse
|
4
|
Nguyen TT, Baumann P, Tüscher O, Schick S, Endres K. The Aging Enteric Nervous System. Int J Mol Sci 2023; 24:ijms24119471. [PMID: 37298421 DOI: 10.3390/ijms24119471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 05/24/2023] [Accepted: 05/25/2023] [Indexed: 06/12/2023] Open
Abstract
The gut and the brain communicate via the nervous system, hormones, microbiota-mediated substances, and the immune system. These intricate interactions have led to the term "gut-brain axis". Unlike the brain-which is somewhat protected-the gut is exposed to a variety of factors throughout life and, consequently, might be either more vulnerable or better adapted to respond to these challenges. Alterations in gut function are common in the elder population and associated with many human pathologies, including neurodegenerative diseases. Different studies suggest that changes in the nervous system of the gut, the enteric nervous system (ENS), during aging may result in gastrointestinal dysfunction and initiate human pathologies of the brain via its interconnection with the gut. This review aims at summarizing the contribution of normal cellular aging to the age-associated physiological changes of the ENS. Morphological alterations and degeneration of the aging ENS are observed in different animal models and humans, albeit with considerable variability. The aging phenotypes and pathophysiological mechanisms of the aging ENS have highlighted the involvement of enteric neurons in age-related diseases of the central nervous system such as Alzheimer's or Parkinson's disease. To further elucidate such mechanisms, the ENS constitutes a promising source of material for diagnosis and therapeutic predictions, as it is more accessible than the brain.
Collapse
Affiliation(s)
- Tinh Thi Nguyen
- Department of Psychiatry and Psychotherapy, University Medical Center Mainz, 55131 Mainz, Germany
- Chromatin Regulation Group, Institute of Molecular Biology, 55128 Mainz, Germany
| | - Peter Baumann
- Chromosome Dynamics, Telomeres & Aging Group, Faculty of Biology and Institute of Molecular Biology, 55128 Mainz, Germany
| | - Oliver Tüscher
- Department of Psychiatry and Psychotherapy, University Medical Center Mainz, 55131 Mainz, Germany
- Institute of Molecular Biology, 55128 Mainz, Germany
- Leibniz Institute for Resilience Research, 55122 Mainz, Germany
| | - Sandra Schick
- Chromatin Regulation Group, Institute of Molecular Biology, 55128 Mainz, Germany
| | - Kristina Endres
- Department of Psychiatry and Psychotherapy, University Medical Center Mainz, 55131 Mainz, Germany
| |
Collapse
|
5
|
Butto T, Mungikar K, Baumann P, Winter J, Lutz B, Gerber S. Nuclei on the Rise: When Nuclei-Based Methods Meet Next-Generation Sequencing. Cells 2023; 12:cells12071051. [PMID: 37048124 PMCID: PMC10093037 DOI: 10.3390/cells12071051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 03/22/2023] [Accepted: 03/27/2023] [Indexed: 04/03/2023] Open
Abstract
In the last decade, we have witnessed an upsurge in nuclei-based studies, particularly coupled with next-generation sequencing. Such studies aim at understanding the molecular states that exist in heterogeneous cell populations by applying increasingly more affordable sequencing approaches, in addition to optimized methodologies developed to isolate and select nuclei. Although these powerful new methods promise unprecedented insights, it is important to understand and critically consider the associated challenges. Here, we provide a comprehensive overview of the rise of nuclei-based studies and elaborate on their advantages and disadvantages, with a specific focus on their utility for transcriptomic sequencing analyses. Improved designs and appropriate use of the various experimental strategies will result in acquiring biologically accurate and meaningful information.
Collapse
Affiliation(s)
- Tamer Butto
- Institute for Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University, 55128 Mainz, Germany
- Correspondence: (T.B.); (S.G.); Tel.: +49-(0)6131-39-27331 (S.G.)
| | - Kanak Mungikar
- Institute of Human Genetics, University Medical Center Mainz, 55131 Mainz, Germany
| | - Peter Baumann
- Faculty of Biology, Johannes Gutenberg-University, 55128 Mainz, Germany
- Institute of Molecular Biology (IMB), 55128 Mainz, Germany
| | - Jennifer Winter
- Institute of Human Genetics, University Medical Center Mainz, 55131 Mainz, Germany
- Leibniz Institute for Resilience Research (LIR), 55122 Mainz, Germany
| | - Beat Lutz
- Leibniz Institute for Resilience Research (LIR), 55122 Mainz, Germany
- Institute of Physiological Chemistry, University Medical Center Mainz, 55128 Mainz, Germany
| | - Susanne Gerber
- Institute of Human Genetics, University Medical Center Mainz, 55131 Mainz, Germany
- Correspondence: (T.B.); (S.G.); Tel.: +49-(0)6131-39-27331 (S.G.)
| |
Collapse
|
6
|
Pan L, Tormey D, Bobon N, Baumann P. Rap1 prevents fusions between long telomeres in fission yeast. EMBO J 2022; 41:e110458. [PMID: 36059259 PMCID: PMC9574727 DOI: 10.15252/embj.2021110458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 08/04/2022] [Accepted: 08/08/2022] [Indexed: 11/15/2022] Open
Abstract
The conserved Rap1 protein is part of the shelterin complex that plays critical roles in chromosome end protection and telomere length regulation. Previous studies have addressed how fission yeast Rap1 contributes to telomere length maintenance, but the mechanism by which the protein inhibits end fusions has remained elusive. Here, we use a mutagenesis screen in combination with high‐throughput sequencing to identify several amino acid positions in Rap1 that have key roles in end protection. Interestingly, mutations at these sites render cells susceptible to genome instability in a conditional manner, whereby longer telomeres are prone to undergoing end fusions, while telomeres within the normal length range are sufficiently protected. The protection of long telomeres is in part dependent on their nuclear envelope attachment mediated by the Rap1–Bqt4 interaction. Our data demonstrate that long telomeres represent a challenge for the maintenance of genome integrity, thereby providing an explanation for species‐specific upper limits on telomere length.
Collapse
Affiliation(s)
- Lili Pan
- Department of Biology, Johannes Gutenberg University, Mainz, Germany
| | - Duncan Tormey
- Stowers Institute for Medical Research, Kansas City, MO, USA
| | - Nadine Bobon
- Department of Biology, Johannes Gutenberg University, Mainz, Germany
| | - Peter Baumann
- Department of Biology, Johannes Gutenberg University, Mainz, Germany.,Institute of Molecular Biology, Mainz, Germany
| |
Collapse
|
7
|
Mozaffari A, Langguth M, Gong B, Ahring J, Campos AR, Nieters P, Escobar OJC, Wittenbrink M, Baumann P, Schultz MG. HPC-oriented Canonical Workflows for Machine Learning Applications in Climate and Weather Prediction. Data Intelligence 2022. [DOI: 10.1162/dint_a_00131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Abstract
Machine learning (ML) applications in weather and climate are gaining momentum as big data and the immense increase in High-performance computing (HPC) power are paving the way. Ensuring FAIR data and reproducible ML practices are significant challenges for Earth system researchers. Even though the FAIR principle is well known to many scientists, research communities are slow to adopt them. Canonical Workflow Framework for Research (CWFR) provides a platform to ensure the FAIRness and reproducibility of these practices without overwhelming researchers. This conceptual paper envisions a holistic CWFR approach towards ML applications in weather and climate, focusing on HPC and big data. Specifically, we discuss Fair Digital Object (FDO) and Research Object (RO) in the DeepRain project to achieve granular reproducibility. DeepRain is a project that aims to improve precipitation forecast in Germany by using ML. Our concept envisages the raster datacube to provide data harmonization and fast and scalable data access. We suggest the Juypter notebook as a single reproducible experiment. In addition, we envision JuypterHub as a scalable and distributed central platform that connects all these elements and the HPC resources to the researchers via an easy-to-use graphical interface.
Collapse
Affiliation(s)
| | | | - Bing Gong
- Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
8
|
De S, Edwards DM, Dwivedi V, Wang J, Varsally W, Dixon HL, Singh AK, Owuamalam PO, Wright MT, Summers RP, Hossain MN, Price EM, Wojewodzic MW, Falciani F, Hodges NJ, Saponaro M, Tanaka K, Azzalin CM, Baumann P, Hebenstreit D, Brogna S. Genome-wide chromosomal association of Upf1 is linked to Pol II transcription in Schizosaccharomyces pombe. Nucleic Acids Res 2021; 50:350-367. [PMID: 34928380 PMCID: PMC8754637 DOI: 10.1093/nar/gkab1249] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 11/30/2021] [Accepted: 12/06/2021] [Indexed: 11/23/2022] Open
Abstract
Although the RNA helicase Upf1 has hitherto been examined mostly in relation to its cytoplasmic role in nonsense mediated mRNA decay (NMD), here we report high-throughput ChIP data indicating genome-wide association of Upf1 with active genes in Schizosaccharomyces pombe. This association is RNase sensitive, correlates with Pol II transcription and mRNA expression levels. Changes in Pol II occupancy were detected in a Upf1 deficient (upf1Δ) strain, prevalently at genes showing a high Upf1 relative to Pol II association in wild-type. Additionally, an increased Ser2 Pol II signal was detected at all highly transcribed genes examined by ChIP-qPCR. Furthermore, upf1Δ cells are hypersensitive to the transcription elongation inhibitor 6-azauracil. A significant proportion of the genes associated with Upf1 in wild-type conditions are also mis-regulated in upf1Δ. These data envisage that by operating on the nascent transcript, Upf1 might influence Pol II phosphorylation and transcription.
Collapse
Affiliation(s)
- Sandip De
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK.,Division of Cellular and Gene Therapies, Tumor Vaccines and Biotechnology Branch, Center for Biologics and Evaluation Research, US Food and Drug Administration, Silver Spring, MD, USA
| | - David M Edwards
- School of Life Sciences, University of Warwick, Coventry, UK
| | - Vibha Dwivedi
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Jianming Wang
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Wazeer Varsally
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Hannah L Dixon
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Anand K Singh
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK.,Interdisciplinary School of Life Sciences, Banaras Hindu University, Varanasi 221005, India
| | - Precious O Owuamalam
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Matthew T Wright
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Reece P Summers
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Md Nazmul Hossain
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK.,Department of Microbial Biotechnology, Faculty of Biotechnology and Genetic Engineering, Sylhet Agricultural University, Sylhet 3100, Bangladesh
| | - Emily M Price
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Marcin W Wojewodzic
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK.,Department of Environmental Health, Norwegian Institute of Public Health, Oslo, Norway & Department of Research, Cancer Registry of Norway, Oslo University Hospital, Oslo, Norway & Environmental Genomics, School of Biosciences, University of Birmingham, Birmingham, UK
| | - Francesco Falciani
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Nikolas J Hodges
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| | - Marco Saponaro
- Institute of Cancer and Genomic Sciences, University of Birmingham, UK
| | - Kayoko Tanaka
- Department of Molecular and Cell Biology, University of Leicester, UK
| | - Claus M Azzalin
- Instituto de Medicina Molecular João Lobo Antunes (iMM), Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
| | | | | | - Saverio Brogna
- School of Biosciences and Birmingham Centre of Genome Biology (BCGB), University of Birmingham, UK
| |
Collapse
|
9
|
Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry 2021; 22:561-628. [PMID: 33977870 DOI: 10.1080/15622975.2021.1878427] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo. Results: Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug.Conclusions: To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine.
Collapse
Affiliation(s)
- C B Eap
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.,Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.,School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland, University of Lausanne, Switzerland, Geneva, Switzerland
| | - G Gründer
- Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - P Baumann
- Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - N Ansermot
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - A Conca
- Department of Psychiatry, Health Service District Bolzano, Bolzano, Italy.,Department of Child and Adolescent Psychiatry, South Tyrolean Regional Health Service, Bolzano, Italy
| | - E Corruble
- INSERM CESP, Team ≪MOODS≫, Service Hospitalo-Universitaire de Psychiatrie, Universite Paris Saclay, Le Kremlin Bicetre, France.,Service Hospitalo-Universitaire de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin Bicêtre, France
| | - S Crettol
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - M L Dahl
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J de Leon
- Eastern State Hospital, University of Kentucky Mental Health Research Center, Lexington, KY, USA
| | - C Greiner
- Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
| | - O Howes
- King's College London and MRC London Institute of Medical Sciences (LMS)-Imperial College, London, UK
| | - E Kim
- Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, South Korea.,Department of Psychiatry, Seoul National University College of Medicine, Seoul, South Korea
| | - R Lanzenberger
- Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
| | - J H Meyer
- Campbell Family Mental Health Research Institute, CAMH and Department of Psychiatry, University of Toronto, Toronto, Canada
| | - R Moessner
- Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
| | - H Mulder
- Department of Clinical Pharmacy, Wilhelmina Hospital Assen, Assen, The Netherlands.,GGZ Drenthe Mental Health Services Drenthe, Assen, The Netherlands.,Department of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy and Pharmaceutical Sciences, University of Groningen, Groningen, The Netherlands.,Department of Psychiatry, Interdisciplinary Centre for Psychopathology and Emotion Regulation, University of Groningen, Groningen, The Netherlands
| | - D J Müller
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - M Reis
- Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.,Clinical Chemistry and Pharmacology, Skåne University Hospital, Lund, Sweden
| | - P Riederer
- Center of Mental Health, Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Würzburg, Germany.,Department of Psychiatry, University of Southern Denmark Odense, Odense, Denmark
| | - H G Ruhe
- Department of Psychiatry, Radboudumc, Nijmegen, the Netherlands.,Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, Netherlands
| | - O Spigset
- Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway.,Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - E Spina
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - B Stegman
- Institut für Pharmazie der Universität Regensburg, Regensburg, Germany
| | - W Steimer
- Institute for Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, Germany
| | - J Stingl
- Institute for Clinical Pharmacology, University Hospital of RWTH Aachen, Germany
| | - S Suzen
- Department of Toxicology, Faculty of Pharmacy, Ankara University, Ankara, Turkey
| | - H Uchida
- Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
| | - S Unterecker
- Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany
| | - F Vandenberghe
- Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - C Hiemke
- Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany
| |
Collapse
|
10
|
Albertsmeier M, Hofmann A, Baumann P, Riedl S, Reisensohn C, Kewer JL, Hoelderle J, Shamiyeh A, Klugsberger B, Maier TD, Schumacher G, Köckerling F, Pession U, Weniger M, Fortelny RH. Effects of the short-stitch technique for midline abdominal closure: short-term results from the randomised-controlled ESTOIH trial. Hernia 2021; 26:87-95. [PMID: 34050419 PMCID: PMC8881264 DOI: 10.1007/s10029-021-02410-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Accepted: 04/08/2021] [Indexed: 11/28/2022]
Abstract
Purpose The short-stitch technique for midline laparotomy closure has been shown to reduce hernia rates, but long stitches remain the standard of care and the effect of the short-stitch technique on short-term results is not well known. The aim of this study was to compare the two techniques, using an ultra-long-term absorbable elastic suture material.
Methods Following elective midline laparotomy, 425 patients in 9 centres were randomised to receive wound closure using the short-stitch (USP 2-0 single thread, n = 215) or long-stitch (USP 1 double loop, n = 210) technique with a poly-4-hydroxybutyrate-based suture material (Monomax®). Here, we report short-term surgical outcomes.
Results At 30 (+10) days postoperatively, 3 (1.40%) of 215 patients in the short-stitch group and 10 (4.76%) of 210 patients in the long-stitch group had developed burst abdomen [OR 0.2830 (0.0768–1.0433), p = 0.0513]. Ruptured suture, seroma and hematoma and other wound healing disorders occurred in small numbers without differences between groups. In a planned Cox proportional hazard model for burst abdomen, the short-stitch group had a significantly lower risk [HR 0.1783 (0.0379–0.6617), p = 0.0115].
Conclusions Although this trial revealed no significant difference in short-term results between the short-stitch and long-stitch techniques for closure of midline laparotomy, a trend towards a lower rate of burst abdomen in the short-stitch group suggests a possible advantage of the short-stitch technique. Trial registry NCT01965249, registered October 18, 2013.
Collapse
Affiliation(s)
- M Albertsmeier
- Department of General, Visceral and Transplantation Surgery, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, 81377, Munich, Germany
| | - A Hofmann
- Allgemein-, Viszeral- und Tumorchirurgie, Wilhelminenspital, Montleartstr. 37, 1160, Vienna, Austria
| | - P Baumann
- Department of Medical Scientific Affairs, Aesculap AG, Am Aesculap Platz, 78532, Tuttlingen, Germany
| | - S Riedl
- Klinik am Eichert, Allgemeinchirurgie, Alb Fils Klinik GmbH, Eichertstr.3, 73035, Göppingen, Germany
| | - C Reisensohn
- Klinik am Eichert, Allgemeinchirurgie, Alb Fils Klinik GmbH, Eichertstr.3, 73035, Göppingen, Germany
| | - J L Kewer
- Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Klinikum Landkreis Tuttlingen, Zeppelinstr. 21, 78532, Tuttlingen, Germany
| | - J Hoelderle
- Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Klinikum Landkreis Tuttlingen, Zeppelinstr. 21, 78532, Tuttlingen, Germany
| | - A Shamiyeh
- Klinik für Allgemein- und Viszeralchirurgie, Kepler Universitätsklinikum GmbH, Krankenhausstr. 9, 4021, Linz, Austria
| | - B Klugsberger
- Klinik für Allgemein- und Viszeralchirurgie, Kepler Universitätsklinikum GmbH, Krankenhausstr. 9, 4021, Linz, Austria
| | - T D Maier
- Allgemein- und Viszeralchirurgie, Robert-Bosch-Krankenhaus, Auerbachstr. 110, 70376, Stuttgart, Germany
| | - G Schumacher
- Chirurgische Klinik, Städtisches Klinikum Braunschweig, Salzdahlumer Str. 90, 38126, Brunswick, Germany
| | - F Köckerling
- Klinik für Chirurgie, Viszeral- und Gefäßchirurgie, Vivantes Klinikum Spandau, Neue Bergstr. 6, 13585, Berlin, Germany
| | - U Pession
- Zentrum der Chirurgie, Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai, 60590, Frankfurt am Main, Germany
| | - M Weniger
- Department of General, Visceral and Transplantation Surgery, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, 81377, Munich, Germany
| | - R H Fortelny
- Allgemein-, Viszeral- und Tumorchirurgie, Wilhelminenspital, Montleartstr. 37, 1160, Vienna, Austria.
- Med. Fakultät, Sigmund Freud Privatuniversität, Freudplatz 3, 1020, Vienna, Austria.
| |
Collapse
|
11
|
Schriever SC, Kabra DG, Pfuhlmann K, Baumann P, Baumgart EV, Nagler J, Seebacher F, Harrison L, Irmler M, Kullmann S, Corrêa-da-Silva F, Giesert F, Jain R, Schug H, Castel J, Martinez S, Wu M, Häring HU, de Angelis MH, Beckers J, Müller TD, Stemmer K, Wurst W, Rozman J, Nogueiras R, De Angelis M, Molkentin JD, Krahmer N, Yi CX, Schmidt MV, Luquet S, Heni M, Tschöp MH, Pfluger PT. Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity. J Clin Invest 2021; 130:6093-6108. [PMID: 32780722 DOI: 10.1172/jci136363] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 07/31/2020] [Indexed: 12/13/2022] Open
Abstract
Recent genome-wide association studies (GWAS) identified DUSP8, encoding a dual-specificity phosphatase targeting mitogen-activated protein kinases, as a type 2 diabetes (T2D) risk gene. Here, we reveal that Dusp8 is a gatekeeper in the hypothalamic control of glucose homeostasis in mice and humans. Male, but not female, Dusp8 loss-of-function mice, either with global or corticotropin-releasing hormone neuron-specific deletion, had impaired systemic glucose tolerance and insulin sensitivity when exposed to high-fat diet (HFD). Mechanistically, we found impaired hypothalamic-pituitary-adrenal axis feedback, blunted sympathetic responsiveness, and chronically elevated corticosterone levels driven by hypothalamic hyperactivation of Jnk signaling. Accordingly, global Jnk1 ablation, AAV-mediated Dusp8 overexpression in the mediobasal hypothalamus, or metyrapone-induced chemical adrenalectomy rescued the impaired glucose homeostasis of obese male Dusp8-KO mice, respectively. The sex-specific role of murine Dusp8 in governing hypothalamic Jnk signaling, insulin sensitivity, and systemic glucose tolerance was consistent with functional MRI data in human volunteers that revealed an association of the DUSP8 rs2334499 risk variant with hypothalamic insulin resistance in men. Further, expression of DUSP8 was increased in the infundibular nucleus of T2D humans. In summary, our findings suggest the GWAS-identified gene Dusp8 as a novel hypothalamic factor that plays a functional role in the etiology of T2D.
Collapse
Affiliation(s)
- Sonja C Schriever
- Research Unit NeuroBiology of Diabetes and.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Dhiraj G Kabra
- Research Unit NeuroBiology of Diabetes and.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Biological Research Pharmacology Department, Sun Pharma Advanced Research Company Ltd., Vadodara, India
| | - Katrin Pfuhlmann
- Research Unit NeuroBiology of Diabetes and.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Division of Metabolic Diseases and
| | - Peter Baumann
- Research Unit NeuroBiology of Diabetes and.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Neurobiology of Diabetes, School of Medicine, Technical University of Munich, Munich, Germany
| | - Emily V Baumgart
- Research Unit NeuroBiology of Diabetes and.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | | | - Fabian Seebacher
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Division of Metabolic Diseases and
| | - Luke Harrison
- Research Unit NeuroBiology of Diabetes and.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Division of Metabolic Diseases and
| | - Martin Irmler
- Institute of Experimental Genetics and German Mouse Clinic, Helmholtz Zentrum München, Neuherberg, Germany
| | - Stephanie Kullmann
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the University of Tübingen, Tübingen, Germany
| | - Felipe Corrêa-da-Silva
- Department of Endocrinology and Metabolism, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.,Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands
| | - Florian Giesert
- Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Department of Developmental Genetics, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany
| | - Ruchi Jain
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Lund University Diabetes Centre, Clinical Research Centre, Skåne University Hospital Malmö, Malmö, Sweden
| | - Hannah Schug
- SYNLAB Analytics and Services, Switzerland AG, Dielsdorf, Switzerland
| | - Julien Castel
- Université de Paris, BFA, UMR 8251, CNRS, Paris, France
| | | | - Moya Wu
- Institute of Experimental Genetics and German Mouse Clinic, Helmholtz Zentrum München, Neuherberg, Germany
| | - Hans-Ulrich Häring
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the University of Tübingen, Tübingen, Germany.,Division of Endocrinology, Diabetology and Nephrology, Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany
| | - Martin Hrabe de Angelis
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute of Experimental Genetics and German Mouse Clinic, Helmholtz Zentrum München, Neuherberg, Germany.,Chair of Experimental Genetics, School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany
| | - Johannes Beckers
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute of Experimental Genetics and German Mouse Clinic, Helmholtz Zentrum München, Neuherberg, Germany.,Chair of Experimental Genetics, School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany
| | - Timo D Müller
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Pharmacology and Experimental Therapy, Eberhard Karls University Hospitals and Clinics, Tübingen, Germany
| | - Kerstin Stemmer
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Wolfgang Wurst
- Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Department of Developmental Genetics, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany.,German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Jan Rozman
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute of Experimental Genetics and German Mouse Clinic, Helmholtz Zentrum München, Neuherberg, Germany.,Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
| | - Ruben Nogueiras
- Department of Physiology, Instituto de Investigación Sanitaria, University of Santiago de Compostela, Santiago de Compostela, Spain
| | | | - Jeffery D Molkentin
- Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.,Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - Natalie Krahmer
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Chun-Xia Yi
- Department of Endocrinology and Metabolism, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.,Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands
| | - Mathias V Schmidt
- Neurobiology of Stress Resilience, Max Planck Institute of Psychiatry, Munich, Germany
| | - Serge Luquet
- Université de Paris, BFA, UMR 8251, CNRS, Paris, France
| | - Martin Heni
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the University of Tübingen, Tübingen, Germany.,Division of Endocrinology, Diabetology and Nephrology, Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany.,Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany
| | - Matthias H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Division of Metabolic Diseases and
| | - Paul T Pfluger
- Research Unit NeuroBiology of Diabetes and.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Neurobiology of Diabetes, School of Medicine, Technical University of Munich, Munich, Germany
| |
Collapse
|
12
|
Baumann P, Schriever SC, Kullmann S, Zimprich A, Peter A, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Wurst W, Tschöp MH, Heni M, Hölter SM, Pfluger PT. Diabetes type 2 risk gene Dusp8 is associated with altered sucrose reward behavior in mice and humans. Brain Behav 2021; 11:e01928. [PMID: 33131190 PMCID: PMC7821601 DOI: 10.1002/brb3.1928] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 09/28/2020] [Accepted: 10/18/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Dusp8 is the first GWAS-identified gene that is predominantly expressed in the brain and has previously been linked with the development of diabetes type 2 in humans. In this study, we unravel how Dusp8 is involved in the regulation of sucrose reward behavior. METHODS Female, chow-fed global Dusp8 WT and KO mice were tested in an observer-independent IntelliCage setup for self-administrative sucrose consumption and preference followed by a progressive ratio task with restricted sucrose access to monitor seeking and motivation behavior. Sixty-three human carriers of the major C and minor T allele of DUSP8 SNP rs2334499 were tested for their perception of food cues by collecting a rating score for sweet versus savory high caloric food. RESULTS Dusp8 KO mice showed a comparable preference for sucrose, but consumed more sucrose compared to WT mice. In a progressive ratio task, Dusp8 KO females switched to a "trial and error" strategy to find sucrose while control Dusp8 WT mice kept their previously established seeking pattern. Nonetheless, the overall motivation to consume sucrose, and the levels of dopaminergic neurons in the brain areas NAcc and VTA were comparable between genotypes. Diabetes-risk allele carriers of DUSP8 SNP rs2334499 preferred sweet high caloric food compared to the major allele carriers, rating scores for savory food remained comparable between groups. CONCLUSION Our data suggest a novel role for Dusp8 in the perception of sweet high caloric food as well as in the control of sucrose consumption and foraging in mice and humans.
Collapse
Affiliation(s)
- Peter Baumann
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Neurobiology of Diabetes, TUM School of Medicine, Technical University of Munich, Munich, Germany
| | - Sonja C Schriever
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Stephanie Kullmann
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.,Department of Internal Medicine IV, University Hospital of Tübingen, Tübingen, Germany
| | - Annemarie Zimprich
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Chair of Developmental Genetics, c/o Helmholtz Zentrum München, Technische Universität München-Weihenstephan, Neuherberg, Germany
| | - Andreas Peter
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.,Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital of Tübingen, Tübingen, Germany
| | - Valerie Gailus-Durner
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg, Germany
| | - Helmut Fuchs
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg, Germany
| | - Martin Hrabe de Angelis
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Chair of Experimental Genetics, School of Life Science Weihenstephan, Technische Universität München, Freising, Germany
| | - Wolfgang Wurst
- Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Chair of Developmental Genetics, c/o Helmholtz Zentrum München, Technische Universität München-Weihenstephan, Neuherberg, Germany.,German Center for Neurodegenerative Diseases (DZNE) Site Munich, Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Matthias H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Division of Metabolic Diseases, Technische Universität München, Munich, Germany
| | - Martin Heni
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany.,Department of Internal Medicine IV, University Hospital of Tübingen, Tübingen, Germany.,Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital of Tübingen, Tübingen, Germany
| | - Sabine M Hölter
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.,Chair of Developmental Genetics, c/o Helmholtz Zentrum München, Technische Universität München-Weihenstephan, Neuherberg, Germany
| | - Paul T Pfluger
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany.,Neurobiology of Diabetes, TUM School of Medicine, Technical University of Munich, Munich, Germany
| |
Collapse
|
13
|
Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche S, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihou M, Soulié M, Richaud P. GETUG-AFU 17 : étude de phase III randomisée comparant la radiothérapie adjuvante à la radiothérapie de rattrapage précoce, combinées à l’hormonothérapie courte, pour les patients présentant un cancer de la prostate traité par prostatectomie radicale. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Sargos P, Chabaud S, Latorzeff I, Magne N, Benyoucef A, Supiot S, Pasquier D, Abdiche S, Gilliot O, Graff P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Nenan S, Richaud P. A Phase III Randomized Trial Comparing Adjuvant versus Early Salvage Radiotherapy, Both Combined with Short-term Androgen Deprivation Therapy, following a Radical Prostatectomy: Initial Results of the GETUG-AFU 17 Study [NCT00667069]. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2100] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Baumann P, Nil R, Bertschy G, Braendli H, Jecker A, Kasas A, Ramseier F, Vuagniaux A. Intravenous Treatment of Depressive Patients with an SSRI, Citalopram: Clinical and Pharmacokinetic Aspects. Eur Psychiatry 2020. [DOI: 10.1016/s0924-9338(97)80243-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
16
|
Baumann P, Nil R. 4 Slow-drop infusion versus oral administration of citalopram: Comparison of plasma concentrations of the enantiomers of citalopram and its metabolites. PHARMACOPSYCHIATRY 2020. [DOI: 10.1055/s-0040-1710112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- P Baumann
- Department of Psychiatry (DP-CHUV), University of Lausanne
| | | |
Collapse
|
17
|
Pan X, Lin H, Yin Y, Cheng M, Baumann P, Jahanzeb M. P2.16-44 Real-World Treatment Patterns and Outcomes in ALK+ NSCLC Patients Receiving Immuno-Oncology Therapy in the United States. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Lin M, Pan X, Hou P, Allen S, Baumann P, Hochmair M. Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Pan X, Lin M, Yin Y, Hou P, Baumann P, Jahanzeb M. Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.037] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Pfuhlmann K, Schriever SC, Baumann P, Kabra DG, Harrison L, Mazibuko-Mbeje SE, Contreras RE, Kyriakou E, Simonds SE, Tiganis T, Cowley MA, Woods SC, Jastroch M, Clemmensen C, De Angelis M, Schramm KW, Sattler M, Messias AC, Tschöp MH, Pfluger PT. Erratum. Celastrol-Induced Weight Loss Is Driven by Hypophagia and Independent From UCP1. Diabetes 2018;67:2456-2465. Diabetes 2019; 68:676. [PMID: 30635274 PMCID: PMC6385754 DOI: 10.2337/db19-er03a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
21
|
Clément-Zhao A, Tanguy ML, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. Abstract P3-12-06: TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-12-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Purpose: Recent phase 3 clinical trials have evaluated the addition of bevacizumab (B) to standard chemotherapy in the treatment of patients with non-metastatic breast cancer. But few data are available about the tolerance of B with locoregional radiation therapy (RT). The objective was to evaluate the 5 years late toxicities of the concurrent B and RT in non-metastatic breast cancer.
Material and methods: This is a multicenter prospective study including non-metastatic breast cancer patients enrolled in phase 3 clinical trials evaluating B with concurrent RT (BEATRICE, BETH, BEVERLY 1, BERVERLY 2) versus RT alone. All patients received neo-adjuvant or adjuvant chemotherapy and normo-fractionated breast or chest wall RT, with or without regional lymph nodes RT. B was administrated as an equivalent of 5 mg/kg every week for 1 year. The safety profile (using the Common Terminology Criteria for Adverse Events version 3.0) was evaluated at 1, 3 and 5 years after the completion of radiotherapy.
Results: From October 2007 to January 2012, 151 patients totally included. Median follow-up was 60 months (36-84) and 5 years late toxicities were available for 104 patients (46 with B and RT, 58 with RT alone). Median age was 51 (22-81). 61% of patients received regional lymph nodes RT. The majority of tumor was triple negative (65.6%), tumor size <2cm (50%) and nodal status negative (63.8%). Median total dose of B was 15000 mg (13200 – 18550) and median duration was 11.2 months (11-12.6). No grade ≥3 toxicity was observed. Only 16 patients had grade 1-2 toxicities (8 treated with B and RT, 8 with RT alone): n=4 (3.8%) had grade 1 pain, n=5 (4.8%) had grade 1-2 fibrosis, n=1 (1%) had grade 2 telangiectasia and n=5 (4.8%) had grade 1-2 lymphoedema. No significant difference between the 2 arms was observed. One patient of 46 evaluated had Left Ventricular Ejection Fraction inferior to 50%. At 5 years, overall survival was 93.8%, disease free-survival 89% and locoregional free-survival 93.1 %.
Conclusion: Concurrent B and locoregional RT provides acceptable 5-years toxicities in patients with non-metastatic breast cancer. No grade ≥3 toxicity was observed.
Citation Format: Clément-Zhao A, Tanguy M-L, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-06.
Collapse
Affiliation(s)
- A Clément-Zhao
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - M-L Tanguy
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - P Cottu
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - B De La Lande
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - P Bontemps
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - C Lemanski
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - P Baumann
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - C Levy
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - K Peignaux
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - A Reynaud-Bougnoux
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - A Gobillion
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - Y Kirova
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| |
Collapse
|
22
|
Jokela M, Baumann P, Huovinen S, Penttilä S, Udd B. Homozygous Nonsense Mutation p.Q274X in TRIM63 (MuRF1) in a Patient with Mild Skeletal Myopathy and Cardiac Hypertrophy. J Neuromuscul Dis 2019; 6:143-146. [DOI: 10.3233/jnd-180350] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Manu Jokela
- Department of Neurology, Neuromuscular Research Center, University Hospital and University of Tampere, Finland
- Division of Clinical Neurosciences, Turku University Hospital, and University of Turku, Turku, Finland
| | - Peter Baumann
- Department of Neurology, Central Hospital of Lapland, Rovaniemi, Finland
| | - Sanna Huovinen
- Department of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Sini Penttilä
- Department of Neurology, Neuromuscular Research Center, University Hospital and University of Tampere, Finland
| | - Bjarne Udd
- Department of Neurology, Neuromuscular Research Center, University Hospital and University of Tampere, Finland
| |
Collapse
|
23
|
Pfuhlmann K, Schriever SC, Baumann P, Kabra DG, Harrison L, Mazibuko-Mbeje SE, Contreras RE, Kyriakou E, Simonds SE, Tiganis T, Cowley MA, Woods SC, Jastroch M, Clemmensen C, De Angelis M, Schramm KW, Sattler M, Messias AC, Tschöp MH, Pfluger PT. Celastrol-Induced Weight Loss Is Driven by Hypophagia and Independent From UCP1. Diabetes 2018; 67:2456-2465. [PMID: 30158241 DOI: 10.2337/db18-0146] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 08/03/2018] [Indexed: 11/13/2022]
Abstract
Celastrol, a plant-derived constituent of traditional Chinese medicine, has been proposed to offer significant potential as an antiobesity drug. However, the molecular mechanism for this activity is unknown. We show that the weight-lowering effects of celastrol are driven by decreased food consumption. Although young Lep ob mice respond with a decrease in food intake and body weight, adult Lep db and Lep ob mice are unresponsive to celastrol, suggesting that functional leptin signaling in adult mice is required to elicit celastrol's catabolic actions. Protein tyrosine phosphatase 1 (PTP1B), a leptin negative-feedback regulator, has been previously reported to be one of celastrol's targets. However, we found that global PTP1B knockout (KO) and wild-type (WT) mice have comparable weight loss and hypophagia when treated with celastrol. Increased levels of uncoupling protein 1 (UCP1) in subcutaneous white and brown adipose tissue suggest celastrol-induced thermogenesis as a further mechanism. However, diet-induced obese UCP1 WT and KO mice have comparable weight loss upon celastrol treatment, and celastrol treatment has no effect on energy expenditure under ambient housing or thermoneutral conditions. Overall, our results suggest that celastrol-induced weight loss is hypophagia driven and age-dependently mediated by functional leptin signaling. Our data encourage reconsideration of therapeutic antiobesity strategies built on leptin sensitization.
Collapse
Affiliation(s)
- Katrin Pfuhlmann
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- Division of Metabolic Diseases, Technische Universität München, Munich, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Sonja C Schriever
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Peter Baumann
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- Division of Metabolic Diseases, Technische Universität München, Munich, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Dhiraj G Kabra
- German Center for Diabetes Research (DZD), Neuherberg, Germany
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany
| | - Luke Harrison
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- Division of Metabolic Diseases, Technische Universität München, Munich, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Sithandiwe E Mazibuko-Mbeje
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
- Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, South Africa
| | - Raian E Contreras
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- Division of Metabolic Diseases, Technische Universität München, Munich, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Eleni Kyriakou
- Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany
- Biomolecular Nuclear Magnetic Resonance and Center for Integrated Protein Science Munich at Department Chemie, Technische Universität München, Garching, Germany
| | - Stephanie E Simonds
- Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia
| | - Tony Tiganis
- Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia
| | - Michael A Cowley
- Department of Physiology, Monash University, Melbourne, Victoria, Australia
| | - Stephen C Woods
- Psychiatry and Behavioral Neuroscience, Metabolic Diseases Institute, University of Cincinnati College of Medicine, Cincinnati, OH
| | - Martin Jastroch
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Christoffer Clemmensen
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Meri De Angelis
- Molecular EXposomics, Helmholtz Zentrum München, Neuherberg, Germany
| | | | - Michael Sattler
- Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany
- Biomolecular Nuclear Magnetic Resonance and Center for Integrated Protein Science Munich at Department Chemie, Technische Universität München, Garching, Germany
| | - Ana C Messias
- Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany
- Biomolecular Nuclear Magnetic Resonance and Center for Integrated Protein Science Munich at Department Chemie, Technische Universität München, Garching, Germany
| | - Matthias H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- Division of Metabolic Diseases, Technische Universität München, Munich, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Paul T Pfluger
- Research Unit Neurobiology of Diabetes, Helmholtz Zentrum München, Neuherberg, Germany
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| |
Collapse
|
24
|
Grenz S, Baumann P, Nebel B, Rückert C, Kalinowski J, Takors R, Blombach B. Aerobe Produktion von Isoprenoiden aus Synthesegas mit Hydrogenophaga pseudoflava
DSM1084. CHEM-ING-TECH 2018. [DOI: 10.1002/cite.201855269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Grenz
- Universität Stuttgart; Institute für Bioverfahrenstechnik; Allmandring 31 70569 Stuttgart Deutschland
| | - P. Baumann
- Universität Stuttgart; Institute für Bioverfahrenstechnik; Allmandring 31 70569 Stuttgart Deutschland
| | - B. Nebel
- Universität Stuttgart; Institut für Biochemie und Technische Biochemie; Allmandring 31 70569 Stuttgart Deutschland
| | - C. Rückert
- Universität Bielefeld; Center for Biotechnology; Universitätsstraße 25 33615 Bielefeld Deutschland
| | - J. Kalinowski
- Universität Bielefeld; Center for Biotechnology; Universitätsstraße 25 33615 Bielefeld Deutschland
| | - R. Takors
- Universität Stuttgart; Institute für Bioverfahrenstechnik; Allmandring 31 70569 Stuttgart Deutschland
| | - B. Blombach
- Universität Stuttgart; Institute für Bioverfahrenstechnik; Allmandring 31 70569 Stuttgart Deutschland
| |
Collapse
|
25
|
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, de la Lande B, Baumann P, Missohou F, Lévy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Pernin V, Kirova Y. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer Radiother 2018; 22:222-228. [PMID: 29650388 DOI: 10.1016/j.canrad.2017.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 10/04/2017] [Indexed: 10/17/2022]
Abstract
PURPOSE To determine the 3 years late toxicity among patients with non-metastatic breast cancer who received concurrent bevacizumab and locoregional radiotherapy. MATERIAL AND METHODS This is a single-arm, multicentre, prospective study, of the toxicity of adjuvant concomitant association of bevacizumab and radiotherapy in patients with breast cancer. Toxicity was assessed by the Common Terminology Criteria for Adverse Events version 3.0 during the radiotherapy and follow-up clinics at 12 and 36 months after its completion. The study was designed to evaluate the toxicity at one year, 3 years and 5 years. RESULTS Sixty-four patients were included from October 2007 to August 2010. All of them received concurrent adjuvant radiotherapy and bevacizumab (in 24 cases after primary systemic treatment). All patients received non-fractionated radiotherapy to breast or chest wall with or without irradiation of regional lymph nodes. Early toxicity has been previously reported. Median follow-up was 46.4 months (range: 18-77 months). Median age was 53 years old (range: 23-68 years). The 3-years overall survival was 93% (range: 87-100%). Evaluation of the toxicity at 3 years was available for 67% of the patients. There was a low rate of toxicity: 14% grade 1 pain, 9% grade 1 fibrosis, 2% grade 1 telangiectasia, 2% grade 1 paresis, 7% grade 1 lymphedema and 2% grade 3 lymphedema. No grade 4 toxicity was observed. No patient had a left ventricular ejection fraction below 50% at 3 years. CONCLUSIONS Concurrent bevacizumab with locoregional radiotherapy is associated with acceptable 3-years toxicity in patients with breast cancer.
Collapse
Affiliation(s)
- A Dautruche
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | - L Belin
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Cottu
- Oncology department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Bontemps
- Radiotherapy department, CHU Jean-Minjoz, 25030 Besançon, France
| | - C Lemanski
- Radiotherapy department, institut régional du cancer de Montpellier, 34298 Montpellier, France
| | - B de la Lande
- Radiotherapy department, institut Curie, René-Huguenin hospital, 92210 Saint-Cloud, France
| | - P Baumann
- Radiotherapy department, centre d'oncologie de Gentilly, 54000 Nancy, France
| | - F Missohou
- Radiotherapy department, centre Henri-Becquerel, 76038 Rouen, France
| | - C Lévy
- Radiotherapy department, centre François-Baclesse, 14000 Caen, France
| | - K Peignaux
- Radiotherapy department, centre Georges-François-Leclerc, 21079 Dijon, France
| | | | - F Denis
- Radiotherapy department, centre Jean-Bernard, 72000 Le Mans, France
| | - A Gobillion
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - V Pernin
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - Y Kirova
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| |
Collapse
|
26
|
Fuchs A, Gotta V, Decker ML, Szinnai G, Baumann P, Bonhoeffer J, Ritz N. Cytokine kinetic profiles in children with acute lower respiratory tract infection: a post hoc descriptive analysis from a randomized control trial. Clin Microbiol Infect 2018; 24:1341.e1-1341.e7. [PMID: 29555393 DOI: 10.1016/j.cmi.2018.03.016] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Revised: 03/08/2018] [Accepted: 03/10/2018] [Indexed: 02/07/2023]
Abstract
OBJECTIVES Standard inflammatory markers and chest radiography lack the ability to discriminate bacterial from non-bacterial lower respiratory tract infection (LRTI). Cytokine profiles may serve as biomarkers for LRTI, but their applicability to identify aetiology, severity of disease and need for antibiotic prescription in children remains poorly defined. Objectives were to determine the cytokine kinetic profiles over 5 days in paediatric patients with LRTI, to investigate the relationship between cytokine patterns, and clinical and laboratory variables. METHODS We included patients aged 1 month to 18 years, with febrile LRTI and three consecutive cytokines measurements on days 1, 3 and 5 of a randomized controlled trial (ProPAED study). We evaluated differences in cytokine concentrations between days and associations with clinical and laboratory variables. RESULTS A total of 181 patients (median age 4.1 years) were included; 72/181 (40%) received antibiotics. Serum concentrations of interferon (IFN)-γ, interleukin (IL)-1ra, IL-6, IL-10, IFN-γ-inducible protein (IP)-10 and tumor necrosis factor-α were elevated on day 1 and decreased subsequently, with the greatest decline between day 1 and 3 (by -8 to >-94%). Procalcitonin (PCT) and C-reactive protein (CRP) values showed a protracted decrease with the most prominent reduction in concentrations between days 3 and 5. Significantly elevated IL-6 concentrations were associated with hospital admission, antibiotic treatment, and prolonged antibiotic treatment. Bacteraemic LRTI patients had higher concentrations of IL-1ra (p <0.0055) and IL-6 (p <0.0055) on day 1. CONCLUSIONS We observed an earlier decrease of elevated cytokines compared to PCT or CRP. Both pro- and anti-inflammatory cytokines may serve as markers for severity of LRTI.
Collapse
Affiliation(s)
- A Fuchs
- Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland
| | - V Gotta
- Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland
| | - M-L Decker
- Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland
| | - G Szinnai
- Paediatric Endocrinology and Diabetology, University of Basel Children's Hospital, Basel, Switzerland
| | - P Baumann
- Paediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland
| | - J Bonhoeffer
- Paediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland
| | - N Ritz
- Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland; Paediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
| |
Collapse
|
27
|
Páez-Moscoso DJ, Pan L, Sigauke RF, Schroeder MR, Tang W, Baumann P. Pof8 is a La-related protein and a constitutive component of telomerase in fission yeast. Nat Commun 2018; 9:587. [PMID: 29422664 PMCID: PMC5805746 DOI: 10.1038/s41467-017-02284-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Accepted: 11/17/2017] [Indexed: 01/06/2023] Open
Abstract
Telomerase reverse transcriptase (TERT) and the non-coding telomerase RNA subunit (TR) constitute the core of telomerase. Here we now report that the putative F-box protein Pof8 is also a constitutive component of active telomerase in fission yeast. Pof8 functions in a hierarchical assembly pathway by promoting the binding of the Lsm2-8 complex to telomerase RNA, which in turn promotes binding of the catalytic subunit. Loss of Pof8 reduces TER1 stability, causes a severe assembly defect, and results in critically short telomeres. Structure profile searches identified similarities between Pof8 and telomerase subunits from ciliated protozoa, making Pof8 next to TERT the most widely conserved telomerase subunits identified to date.
Collapse
Affiliation(s)
| | - Lili Pan
- Stowers Institute for Medical Research, Kansas City, MO, 64110, USA
| | | | | | - Wen Tang
- Stowers Institute for Medical Research, Kansas City, MO, 64110, USA.,RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, 01605, USA
| | - Peter Baumann
- Stowers Institute for Medical Research, Kansas City, MO, 64110, USA. .,Howard Hughes Medical Institute, Kansas City, MO, 64110, USA. .,Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, MO, 66160, USA. .,Institute of Developmental Biology and Neurobiology, Johannes Gutenberg University, 55099, Mainz, Germany.
| |
Collapse
|
28
|
Pfuhlmann K, Schriever SC, Legutko B, Baumann P, Harrison L, Kabra DG, Baumgart EV, Tschöp MH, Garcia-Caceres C, Pfluger PT. Calcineurin A beta deficiency ameliorates HFD-induced hypothalamic astrocytosis in mice. J Neuroinflammation 2018; 15:35. [PMID: 29422055 PMCID: PMC5806488 DOI: 10.1186/s12974-018-1076-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Accepted: 01/22/2018] [Indexed: 11/16/2022] Open
Abstract
Astrocytosis is a reactive process involving cellular, molecular, and functional changes to facilitate neuronal survival, myelin preservation, blood brain barrier function and protective glial scar formation upon brain insult. The overall pro- or anti-inflammatory impact of reactive astrocytes appears to be driven in a context- and disease-driven manner by modulation of astrocytic Ca2+ homeostasis and activation of Ca2+/calmodulin-activated serine/threonine phosphatase calcineurin. Here, we aimed to assess whether calcineurin is dispensable for astrocytosis in the hypothalamus driven by prolonged high fat diet (HFD) feeding. Global deletion of calcineurin A beta (gene name: Ppp3cb) led to a decrease of glial fibrillary acidic protein (GFAP)-positive cells in the ventromedial hypothalamus (VMH), dorsomedial hypothalamus (DMH), and arcuate nucleus (ARC) of mice exposed chronically to HFD. The concomitant decrease in Iba1-positive microglia in the VMH further suggests a modest impact of Ppp3cb deletion on microgliosis. Pharmacological inhibition of calcineurin activity by Fk506 had no impact on IBA1-positive microglia in hypothalami of mice acutely exposed to HFD for 1 week. However, Fk506-treated mice displayed a decrease in GFAP levels in the ARC. In vivo effects could not be replicated in cell culture, where calcineurin inhibition by Fk506 had no effect on astrocytic morphology, astrocytic cell death, GFAP, and vimentin protein levels or microglia numbers in primary hypothalamic astrocytes and microglia co-cultures. Further, adenoviral overexpression of calcineurin subunit Ppp3r1 in primary glia culture did not lead to an increase in GFAP fluorescence intensity. Overall, our results point to a prominent role of calcineurin in mediating hypothalamic astrocytosis as response to acute and chronic HFD exposure. Moreover, discrepant findings in vivo and in cell culture indicate the necessity of studying astrocytes in their “natural” environment, i.e., preserving an intact hypothalamic microenvironment with neurons and non-neuronal cells in close proximity.
Collapse
Affiliation(s)
- Katrin Pfuhlmann
- Research Unit NeuroBiology of Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Division of Metabolic Diseases, Technische Universität München, 80333, Munich, Germany.,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany
| | - Sonja C Schriever
- Research Unit NeuroBiology of Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany
| | - Beata Legutko
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Division of Metabolic Diseases, Technische Universität München, 80333, Munich, Germany.,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany
| | - Peter Baumann
- Research Unit NeuroBiology of Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Division of Metabolic Diseases, Technische Universität München, 80333, Munich, Germany.,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany
| | - Luke Harrison
- Research Unit NeuroBiology of Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Division of Metabolic Diseases, Technische Universität München, 80333, Munich, Germany.,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany
| | - Dhiraj G Kabra
- German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany.,Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center. Heinrich Heine University, Leibniz Center for Diabetes Research, 40225, Düsseldorf, Germany
| | - Emily Violette Baumgart
- Research Unit NeuroBiology of Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany
| | - Matthias H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany.,Division of Metabolic Diseases, Technische Universität München, 80333, Munich, Germany.,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany
| | - Cristina Garcia-Caceres
- Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany. .,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany.
| | - Paul T Pfluger
- Research Unit NeuroBiology of Diabetes, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany. .,Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764, Neuherberg, Germany. .,German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany.
| |
Collapse
|
29
|
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51:e1. [PMID: 29390205 DOI: 10.1055/s-0037-1600991] [Citation(s) in RCA: 100] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- C Hiemke
- Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany.,Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany
| | - N Bergemann
- Kitzberg Hospitals, Center for Psychosomatic Medicine and Psychotherapy, Bad Mergentheim, Germany
| | - H W Clement
- Department of Child and Adolescent Psychiatry, University of Freiburg, Freiburg, Germany
| | - A Conca
- Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
| | - J Deckert
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - K Domschke
- Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | | | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - C Greiner
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - G Gründer
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - E Haen
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - U Havemann-Reinecke
- Department of Psychiatry and Psychosomatics, University of Göttingen, Göttingen, Germany
| | - G Hefner
- Psychiatric Hospital, Vitos Klinik, Eichberg, Eltville, Germany
| | - R Helmer
- Center of Epilepsy, Bielefeld, Germany
| | - G Janssen
- Medical Laboratory Stein, Limbach Group, Mönchengladbach, Germany
| | - E Jaquenoud
- Psychiatric Hospital, Königsfelden, Brugg, Aargau, Switzerland
| | - G Laux
- Institute of Psychological Medicine, Haag in Oberbayern, Germany
| | - T Messer
- Danuviuskliniken, Psychiatric Hospital, Pfaffenhofen, Germany
| | - R Mössner
- Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
| | - M J Müller
- Psychiatric Hospitals Oberberggruppe, Berlin, Germany
| | - M Paulzen
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - B Pfuhlmann
- Psychiatric Hospital Weisser Hirsch, Dresden, Germany
| | - P Riederer
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - A Saria
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria
| | - B Schoppek
- kbo-Isar-Amper Klinikum München-Ost, Psychiatric Hospital, Munich-Haar, Germany
| | | | - M Schwarz
- Department of Laboratory Medicine, Ludwig Maximilian University, Munich, Germany
| | - M Silva Gracia
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - B Stegmann
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - W Steimer
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany
| | - J C Stingl
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - M Uhr
- Max Planck Institute of Psychiatry, Munich, Germany
| | - S Ulrich
- Aristo Pharma GmbH, Berlin, Germany
| | - S Unterecker
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | | | - G Zernig
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria.,Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria
| | - G Zurek
- Medical Laboratory Bremen, Bremen, Germany
| | - P Baumann
- Department of Psychiatry, University of Lausanne, Prilly-Lausanne, Switzerland
| |
Collapse
|
30
|
Schmidmaier R, Mörsdorf K, Baumann P, Emmerich B, Meinhardt G. Evidence for Cell Adhesion-Mediated Drug Resistance of Multiple Myeloma Cells in Vivo. Int J Biol Markers 2018; 21:218-22. [PMID: 17177159 DOI: 10.1177/172460080602100404] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background/Aims Multiple myeloma is an incurable disease and patients eventually die of disease progression due to drug resistance. VLA-4 (very late antigen 4), VCAM (vascular adhesion molecule), LFA-1 (leukocyte function-associated antigen 1), and ICAM-1 (intercellular adhesion molecule 1)-mediated adhesion of myeloma cells to bone marrow stromal cells induces primary multidrug resistance in vitro. Based on these preclinical data we hypothesized that myeloma cells with strong adhesion - due to strong expression of adhesion molecules on the cell surface - are selected by chemotherapy in patients. To prove this hypothesis we determined the expression levels of adhesion molecules in 31 multiple myeloma patients by flow cytometry. Methods A 3-color stain with CD38, CD138 and antibodies against VLA-4, ICAM-1, LFA-1, and VCAM was performed. The patients were either at diagnosis (chemo-naive; n=17) or at relapse (pre-treated; n=15). Furthermore, the response to the next chemotherapy of chemo-naive patients was correlated with the expression levels of adhesion molecules. Results ICAM-1, VLA-4, and VCAM expression was higher in pre-treated patients than in chemo-naive patients and the expression levels increased with the number of chemotherapy regimens. Primarily multidrug-resistant patients had significantly higher expression levels of VLA-4 and ICAM-1 than responders. Conclusion This study suggests that multiple myeloma cells expressing high levels of VLA-4 and ICAM-1 are drug resistant and that such a subpopulation of cells is selected by chemotherapy.
Collapse
Affiliation(s)
- R Schmidmaier
- Department of Hematology and Oncology, Medizinische Klinik Innenstadt, Klinikum der Universität München, München, Germany.
| | | | | | | | | |
Collapse
|
31
|
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2017; 51:9-62. [PMID: 28910830 DOI: 10.1055/s-0043-116492] [Citation(s) in RCA: 533] [Impact Index Per Article: 76.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM. However, the potential benefits of TDM to optimize pharmacotherapy can only be obtained if the method is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid information on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued their first guidelines for TDM in psychiatry in 2004. After an update in 2011, it was time for the next update. Following the new guidelines holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.
Collapse
Affiliation(s)
- C Hiemke
- Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany.,Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany
| | - N Bergemann
- Kitzberg Hospitals, Center for Psychosomatic Medicine and Psychotherapy, Bad Mergentheim, Germany
| | - H W Clement
- Department of Child and Adolescent Psychiatry, University of Freiburg, Freiburg, Germany
| | - A Conca
- Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
| | - J Deckert
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - K Domschke
- Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | | | - K Egberts
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - M Gerlach
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
| | - C Greiner
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - G Gründer
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - E Haen
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - U Havemann-Reinecke
- Department of Psychiatry and Psychosomatics, University of Göttingen, Göttingen, Germany
| | - G Hefner
- Psychiatric Hospital, Vitos Klinik, Eichberg, Eltville, Germany
| | - R Helmer
- Center of Epilepsy, Bielefeld, Germany
| | - G Janssen
- Medical Laboratory Stein, Limbach Group, Mönchengladbach, Germany
| | - E Jaquenoud
- Psychiatric Hospital, Königsfelden, Brugg, Aargau, Switzerland
| | - G Laux
- Institute of Psychological Medicine, Haag in Oberbayern, Germany
| | - T Messer
- Danuviuskliniken, Psychiatric Hospital, Pfaffenhofen, Germany
| | - R Mössner
- Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
| | - M J Müller
- Psychiatric Hospitals Oberberggruppe, Berlin, Germany
| | - M Paulzen
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA - Translational Brain Medicine, Aachen, Germany
| | - B Pfuhlmann
- Psychiatric Hospital Weisser Hirsch, Dresden, Germany
| | - P Riederer
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | - A Saria
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria
| | - B Schoppek
- kbo-Isar-Amper Klinikum München-Ost, Psychiatric Hospital, Munich-Haar, Germany
| | | | - M Schwarz
- Department of Laboratory Medicine, Ludwig Maximilian University, Munich, Germany
| | - M Silva Gracia
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - B Stegmann
- Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
| | - W Steimer
- Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany
| | - J C Stingl
- Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - M Uhr
- Max Planck Institute of Psychiatry, Munich, Germany
| | - S Ulrich
- Aristo Pharma GmbH, Berlin, Germany
| | - S Unterecker
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany
| | | | - G Zernig
- Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria.,Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria
| | - G Zurek
- Medical Laboratory Bremen, Bremen, Germany
| | - P Baumann
- Department of Psychiatry, University of Lausanne, Prilly-Lausanne, Switzerland
| |
Collapse
|
32
|
Dupont E, Otuka N, Cabellos O, Aberle O, Aerts G, Altstadt S, Alvarez H, Alvarez-Velarde F, Andriamonje S, Andrzejewski J, Audouin L, Bacak M, Badurek G, Balibrea J, Barbagallo M, Barros S, Baumann P, Bécares V, Bečvář F, Beinrucker C, Belloni F, Berthier B, Berthoumieux E, Billowes J, Boccone V, Bosnar D, Brown A, Brugger M, Caamaño M, Calviani M, Calviño F, Cano-Ott D, Capote R, Cardella R, Carrapiço C, Casanovas A, Castelluccio D, Cennini P, Cerutti F, Chen Y, Chiaveri E, Chin M, Colonna N, Cortés G, Cortés-Giraldo M, Cosentino L, Couture A, Cox J, Damone L, David S, Deo K, Diakaki M, Dillmann I, Domingo-Pardo C, Dressler R, Dridi W, Duran I, Eleftheriadis C, Embid-Segura M, Fernández-Domínguez B, Ferrant L, Ferrari A, Ferreira P, Finocchiaro P, Fraval K, Frost R, Fujii K, Furman W, Ganesan S, Garcia A, Gawlik A, Gheorghe I, Gilardoni S, Giubrone G, Glodariu T, Göbel K, Gomez-Hornillos M, Goncalves I, Gonzalez-Romero E, Goverdovski A, Gramegna F, Griesmayer E, Guerrero C, Gunsing F, Gurusamy P, Haight R, Harada H, Heftrich T, Heil M, Heinitz S, Hernández-Prieto A, Heyse J, Igashira M, Isaev S, Jenkins D, Jericha E, Kadi Y, Kaeppeler F, Kalamara A, Karadimos D, Karamanis D, Katabuchi T, Kavrigin P, Kerveno M, Ketlerov V, Khryachkov V, Kimura A, Kivel N, Kokkoris M, Konovalov V, Krtička M, Kroll J, Kurtulgil D, Lampoudis C, Langer C, Leal-Cidoncha E, Lederer C, Leeb H, Naour CL, Lerendegui-Marco J, Leong L, Licata M, Meo SL, Lonsdale S, Losito R, Lozano M, Macina D, Manousos A, Marganiec J, Martinez T, Marrone S, Masi A, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri E, Mazzone A, Mendoza E, Mengoni A, Milazzo P, Mingrone F, Mirea M, Mondelaers W, Montesano S, Moreau C, Mosconi M, Musumarra A, Negret A, Nolte R, O’Brien S, Oprea A, Palomo-Pinto F, Pancin J, Paradela C, Patronis N, Pavlik A, Pavlopoulos P, Perkowski J, Perrot L, Pigni M, Plag R, Plompen A, Plukis L, Poch A, Porras I, Praena J, Pretel C, Quesada J, Radeck D, Rajeev K, Rauscher T, Reifarth R, Riego A, Robles M, Roman F, Rout P, Rudolf G, Rubbia C, Rullhusen P, Ryan J, Sabaté-Gilarte M, Salgado J, Santos C, Sarchiapone L, Sarmento R, Saxena A, Schillebeeckx P, Schmidt S, Schumann D, Sedyshev P, Smith A, Sosnin N, Stamatopoulos A, Stephan C, Suryanarayana S, Tagliente G, Tain J, Tarifeño-Saldivia A, Tarrío D, Tassan-Got L, Tavora L, Terlizzi R, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Versaci R, Vermeulen M, Villamarin D, Vicente M, Vlachoudis V, Vlastou R, Voss F, Wallner A, Walter S, Ware T, Warren S, Weigand M, Weiß C, Wolf C, Wiesher M, Wisshak K, Woods P, Wright T, Žugec P. Dissemination of data measured at the CERN n_TOF facility. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714607002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Pasanen P, Mäkinen J, Myllykangas L, Guerreiro R, Bras J, Valori M, Viitanen M, Baumann M, Tienari PJ, Pöyhönen M, Baumann P. Primary familial brain calcification linked to deletion of 5' noncoding region of SLC20A2. Acta Neurol Scand 2017; 136:59-63. [PMID: 27726124 DOI: 10.1111/ane.12697] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/19/2016] [Indexed: 12/17/2022]
Abstract
OBJECTIVES Primary familial brain calcification (PFBC) is a rare neurological disease often inherited as a dominant trait. Mutations in four genes (SLC20A2, PDGFB, PDGFRB, and XPR1) have been reported in patients with PFBC. Of these, point mutations or small deletions in SLC20A2 are most common. Thus far, only one large deletion covering entire SLC20A2 and several smaller, exonic deletions of SLC20A2 have been reported. The aim of this study was to identify the causative gene defect in a Finnish PFBC family with three affected patients. MATERIALS AND METHODS A Finnish family with three PFBC patients and five unaffected subjects was studied. Sanger sequencing was used to exclude mutations in the coding and splice site regions of SLC20A2, PDGFRB, and PDGFB. Whole-exome (WES) and whole-genome sequencing (WGS) were performed to identify the causative mutation. A SNP array was used in segregation analysis. RESULTS Copy number analysis of the WGS data revealed a heterozygous deletion of ~578 kb on chromosome 8. The deletion removes the 5' UTR region, the noncoding exon 1 and the putative promoter region of SLC20A2 as well as the coding regions of six other genes. CONCLUSIONS Our results support haploinsufficiency of SLC20A2 as a pathogenetic mechanism in PFBC. Analysis of copy number variations (CNVs) is emerging as a crucial step in the molecular genetic diagnostics of PFBC, and it should not be limited to coding regions, as causative variants may reside in the noncoding parts of known disease-associated genes.
Collapse
Affiliation(s)
- P. Pasanen
- Department of Medical Biochemistry and Genetics; University of Turku; Turku Finland
- Tyks Microbiology and Genetics; Department of Medical Genetics; Turku University Hospital; Turku Finland
| | - J. Mäkinen
- Department of Neurology; Tampere University Hospital; Tampere Finland
| | - L. Myllykangas
- Department of Pathology; University of Helsinki and HUSLAB; Helsinki Finland
| | - R. Guerreiro
- Department of Molecular Neuroscience; UCL Institute of Neurology; London UK
- Department of Medical Sciences and Institute of Biomedicine - iBiMED; University of Aveiro; Aveiro Portugal
| | - J. Bras
- Department of Molecular Neuroscience; UCL Institute of Neurology; London UK
- Department of Medical Sciences and Institute of Biomedicine - iBiMED; University of Aveiro; Aveiro Portugal
| | - M. Valori
- Research Programs Unit; Molecular Neurology; University of Helsinki; Helsinki Finland
| | - M. Viitanen
- Department of Geriatrics; University of Turku; Turku Finland
- Department of Neurobiology; Care Sciences and Society; Karolinska Institutet; Stockholm Sweden
| | - M. Baumann
- Biochemistry/Developmental Biology; Meilahti Clinical Proteomics Core Facility; University of Helsinki; Helsinki Finland
| | - P. J. Tienari
- Research Programs Unit; Molecular Neurology; University of Helsinki; Helsinki Finland
- Clinical Neurosciences; Neurology; University of Helsinki and Helsinki University Hospital; Helsinki Finland
| | - M. Pöyhönen
- Department of Clinical Genetics; Helsinki University Central Hospital and Department of Medical Genetics; University of Helsinki; Helsinki Finland
| | - P. Baumann
- Department of Neurology and Clinical Neurophysiology; Lapland Central Hospital; Rovaniemi Finland
| |
Collapse
|
34
|
Rumpler M, Hajnsek M, Baumann P, Pieber TR, Klimant I. Monitoring tissue oxygen heterogeneities and their influence on optical glucose measurements in an animal model. J Clin Monit Comput 2017; 32:583-586. [DOI: 10.1007/s10877-017-0034-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Accepted: 05/30/2017] [Indexed: 01/16/2023]
|
35
|
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Abstract P1-10-17: Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-10-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose/Objectives
The purpose of this study was to determine early and late toxicities among patients with non-metastatic breast cancer (BC) receiving concurrent bevacizumab (BV) and radiation therapy (RT).
Materials/Methods
Multicentre, prospective study, of the toxicity of adjuvant concomitant association of BV and RT in patients with non-metastatic BC enrolled in Phase 3 BEATRICE, BEVERLY and BETH trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during RT, 12 months and 36 months after its completion.
Results
Sixty-four patients were included from october 2007 to august 2010. They all received adjuvant RT and BV concomitant treatment, plus neo-adjuvant BV for 24 patients. RT was adjuvant and normo-fractionated. Twelve months toxicity was available for 60 patients and 36 months toxicity was available for 43 patients. Median follow-up was 46 months (18-77). Median age was 51 years old (23-68). Among 63 evaluated patients during RT, acute radiation dermatitis was observed in 48 (76%) patients : Grade 1 for 27 (43%), grade 2 for 17 (27%), grade 3 for 4 patients (6%). Grade 2 acute oesophagitis was observed in 1 patient. At 3 years, few toxicities were observed : 6 patients (14%) had grade 1 pain, 4 (9%) had grade 1 fibrosis, one (2%) had grade 1 telangiectasis, one (2%) had grade 1 paresis, 3 (7%) had grade 1 lymphoedema and one grade 3 lymphoedema. No grade 4 toxicity was observed. At 12 months, only one evaluated patient had a LVEF <50% and none at 36 months.
Conclusions
Concurrent bevacizumab with locoregional RT is associated with acceptable early and late 3-years toxicities in patients with BC. Determination of late toxicity at 60 months is currently underway.
Citation Format: Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-10-17.
Collapse
Affiliation(s)
- A Dautruche
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - L Belin
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Cottu
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Bontemps
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - C Lemanski
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - B De La Lande
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Baumann
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - F Missohou
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - C Levy
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - K Peignaux
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Reynaud-Bougnoux
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - F Denis
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Gobillion
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - N Ady Vago
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Fourquet
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - Y Kirova
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| |
Collapse
|
36
|
Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Forsberg K, Baumann P, Pinto S, de Carvalho M, Hübers A, Nordin F, Ludolph AC, Weishaupt JH, Meyer T, Grehl T, Schweikert K, Weber M, Burkhardt C, Neuwirth C, Holmøy T, Morita M, Tysnes OB, Benatar M, Wuu J, Lange DJ, Bisgård C, Asgari N, Tarvainen I, Brännström T, Andersen PM. Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotroph Lateral Scler Frontotemporal Degener 2016; 18:256-264. [PMID: 27936955 DOI: 10.1080/21678421.2016.1262423] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A large GGGGCC-repeat expansion mutation (HREM) in C9orf72 is the most common known cause of ALS and FTD in European populations. Sequence variations immediately downstream of the HREM region have previously been observed and have been suggested to be one reason for difficulties in interpreting RP-PCR data. Our objective was to determine the properties of these sequence variations with regard to prevalence, the range of variation, and effect on disease prognosis. We screened a multi-national cohort (n = 6981) for the HREM and samples with deviant RP-PCR curves were identified. The deviant samples were subsequently sequenced to determine sequence alteration. Our results show that in the USA and European cohorts (n = 6508) 10.7% carried the HREM and 3% had a sequence variant, while no HREM or sequence variants were observed in the Japanese cohort (n = 473). Sequence variations were more common on HREM alleles; however, certain population specific variants were associated with a non-expanded allele.In conclusion, we identified 38 different sequence variants, most located within the first 50 bp downstream of the HREM region. Furthermore, the presence of an HREM was found to be coupled to a lower age of onset and a shorter disease survival, while sequence variation did not have any correlation with these parameters.
Collapse
Affiliation(s)
- Angelica Nordin
- a Department of Pharmacology and Clinical Neuroscience , Umeå University , Umeå , Sweden
| | - Chizuru Akimoto
- b Division of Neurology, Department of Internal Medicine , Jichi Medical University , Tochigi , Japan
| | - Anna Wuolikainen
- c Department of Chemistry , Umeå University , Umeå , Sweden.,d Computational Life Science Cluster (CLIC) , Umeå University , Umeå , Sweden
| | - Helena Alstermark
- a Department of Pharmacology and Clinical Neuroscience , Umeå University , Umeå , Sweden
| | - Karin Forsberg
- e Department of Medical Biosciences , Umeå University , Umeå , Sweden
| | - Peter Baumann
- f Department of Neurology , Central Hospital of Lapland , Rovaniemi , Finland
| | - Susana Pinto
- g Institute of Physiology and Institute of Molecular Medicine , University of Lisbon , Lisbon , Portugal
| | - Mamede de Carvalho
- g Institute of Physiology and Institute of Molecular Medicine , University of Lisbon , Lisbon , Portugal.,h Department of Neurosciences , Hospital de Santa Maria-CHLN , Lisbon , Portugal
| | | | - Frida Nordin
- a Department of Pharmacology and Clinical Neuroscience , Umeå University , Umeå , Sweden
| | | | | | - Thomas Meyer
- j Outpatient Department for ALS and other Motor Neuron Diseases , Charité-Universitätsmedizin Berlin , Berlin , Germany
| | | | - Kathi Schweikert
- l Department of Neurology , Neuromuscular Center, Basel University Hospital, University Basel , Basel , Switzerland
| | - Markus Weber
- m Kantonsspital St. Gallen , Neuromuscular Disease Centre/ALS Clinic , Switzerland
| | - Christian Burkhardt
- m Kantonsspital St. Gallen , Neuromuscular Disease Centre/ALS Clinic , Switzerland
| | - Christoph Neuwirth
- m Kantonsspital St. Gallen , Neuromuscular Disease Centre/ALS Clinic , Switzerland
| | - Trygve Holmøy
- n Department of Neurology , Akershus University Hospital , Lørenskog , Norway.,o Institute of Clinical Medicine , University of Oslo , Norway
| | - Mitsuya Morita
- b Division of Neurology, Department of Internal Medicine , Jichi Medical University , Tochigi , Japan
| | - Ole-Bjørn Tysnes
- p Department of Neurology , Haukeland University Hospital , Bergen , Norway.,q Department of Clinical Medicine , University of Bergen , Bergen , Norway
| | - Michael Benatar
- r Department of Neurology , University of Miami , Miami , FL , USA
| | - Joanne Wuu
- r Department of Neurology , University of Miami , Miami , FL , USA
| | - Dale J Lange
- s Department of Neurology , Hospital for Special Surgery , New York , USA.,t Department of Neurology , New York-Presbyterian Hospital, Weill-Cornell Medical Center , New York , USA
| | - Carsten Bisgård
- u Department of Neurology , Lillebælt Hospital , Vejle , Denmark
| | - Nasrin Asgari
- u Department of Neurology , Lillebælt Hospital , Vejle , Denmark.,v Department of Neurobiology , Institute of Molecular Medicine, University of Southern Denmark , Odense , Denmark , and
| | - Ilkka Tarvainen
- w Department of Neurology , Mikkeli Central Hospital , Finland
| | - Thomas Brännström
- e Department of Medical Biosciences , Umeå University , Umeå , Sweden
| | - Peter M Andersen
- a Department of Pharmacology and Clinical Neuroscience , Umeå University , Umeå , Sweden.,i Department of Neurology , Ulm University , Ulm , Germany
| |
Collapse
|
37
|
Palmio J, Kärppä M, Baumann P, Penttilä S, Moilanen J, Udd B. Novel compound heterozygous mutation in SACS gene leads to a milder autosomal recessive spastic ataxia of Charlevoix-Saguenay, ARSACS, in a Finnish family. Clin Case Rep 2016; 4:1151-1156. [PMID: 27980752 PMCID: PMC5134137 DOI: 10.1002/ccr3.722] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 08/31/2016] [Accepted: 09/20/2016] [Indexed: 11/06/2022] Open
Abstract
Autosomal recessive spastic ataxia of Charlevoix-Saguenay is a rare disorder outside Quebec causing childhood-onset cerebellar ataxia, peripheral neuropathy, and pyramidal tract signs. A Finnish family with milder form of ARSACS was found to harbor three mutations, p.E1100K, p.N1489S, and p.M1359T, in SACS gene. The mutations segregated with the disease.
Collapse
Affiliation(s)
- Johanna Palmio
- Department of Neurology Neuromuscular Research Center Tampere University and University Hospital Tampere Finland
| | - Mikko Kärppä
- Department of Neurology Oulu University Hospital and University of Oulu Oulu Finland
| | - Peter Baumann
- Department of Neurology Lapland Central Hospital Rovaniemi Finland
| | - Sini Penttilä
- Department of Neurology Neuromuscular Research Center Tampere University and University Hospital Tampere Finland
| | - Jukka Moilanen
- Department of Clinical Genetics and Medical Research Center Oulu Oulu University Hospital and University of Oulu Oulu Finland
| | - Bjarne Udd
- Department of Neurology Neuromuscular Research Center Tampere University and University Hospital Tampere Finland; Folkhälsan Institute of Genetics and the Department of Medical Genetics Haartman Institute University of Helsinki Helsinki Finland; Department of Neurology Vaasa Central Hospital Vaasa Finland
| |
Collapse
|
38
|
Newton AA, Schnittker RR, Yu Z, Munday SS, Baumann DP, Neaves WB, Baumann P. Widespread failure to complete meiosis does not impair fecundity in parthenogenetic whiptail lizards. Development 2016; 143:4486-4494. [PMID: 27802173 PMCID: PMC5201048 DOI: 10.1242/dev.141283] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 10/12/2016] [Indexed: 11/20/2022]
Abstract
Parthenogenetic species of whiptail lizards in the genus Aspidoscelis constitute a striking example of speciation by hybridization, in which first-generation hybrids instantly attain reproductive isolation and procreate as clonal all-female lineages. Production of eggs containing a full complement of chromosomes in the absence of fertilization involves genome duplication prior to the meiotic divisions. In these pseudo-tetraploid oocytes, pairing and recombination occur exclusively between identical chromosomes instead of homologs; a deviation from the normal meiotic program that maintains heterozygosity. Whether pseudo-tetraploid cells arise early in germ cell development or just prior to meiosis has remained unclear. We now show that in the obligate parthenogenetic species A. neomexicana the vast majority of oocytes enter meiosis as diploid cells. Telomere bouquet formation is normal, but synapsis fails and oocytes accumulate in large numbers at the pairing stage. Pseudo-tetraploid cells are exceedingly rare in early meiotic prophase, but they are the only cells that progress into diplotene. Despite the widespread failure to increase ploidy prior to entering meiosis, the fecundity of parthenogenetic A. neomexicana is similar to that of A. inornata, one of its bisexual ancestors.
Collapse
Affiliation(s)
- Aracely A Newton
- Stowers Institute for Medical Research, Kansas City, MO 64110, USA
| | | | - Zulin Yu
- Stowers Institute for Medical Research, Kansas City, MO 64110, USA
| | - Sarah S Munday
- Stowers Institute for Medical Research, Kansas City, MO 64110, USA
| | - Diana P Baumann
- Stowers Institute for Medical Research, Kansas City, MO 64110, USA
| | - William B Neaves
- Stowers Institute for Medical Research, Kansas City, MO 64110, USA
| | - Peter Baumann
- Stowers Institute for Medical Research, Kansas City, MO 64110, USA .,Howard Hughes Medical Institute, Kansas City, MO 64110, USA.,Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA
| |
Collapse
|
39
|
Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP, Saed GM. Effects of Prostaglandin E2 on Proliferation and Apoptosis of Epithelial Ovarian Cancer Cells. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/107155760200900309] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | | | | | | | | | - M. P. Diamond
- Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan
| | - G. M. Saed
- Department of Obsterics and Gnecology, Wayne State University, 4707 St. Antoine -5 West, Detroit, MI 48201
| |
Collapse
|
40
|
Abstract
The 1‑year incisional hernia rate of 9-30 % has been tolerated for decades. Even in the 1970s and 1980s there was evidence that supported reducing suture tension. Recently, the traditional 4:1 relationship between suture and wound length, which has been passed on for years, has been questioned. After first experimental and clinical data suggested an advantage by reducing the width and interval of stitches by 50 %, the prospective randomized STITCH study has now provided evidence by significantly lowering the 1‑year hernia rate from 21 % to 13 %. For surgeons this means less of a revolution and more of an innovative evolution of a long-established technique. Before introduction of the technique quality assurance must be carried out with documentation of performance indicators (e.g. number of stitches, length of thread incorporated and wound length).
Collapse
Affiliation(s)
- M Golling
- Klinik für Allgemein- und Viszeralchirurgie, Das DIAK, Diakonieklinikum Schwäbisch Hall, Diakoniestr. 10, 74523, Schwäbisch Hall, Deutschland.
| | - S Felbinger
- Klinik für Allgemein- und Viszeralchirurgie, Das DIAK, Diakonieklinikum Schwäbisch Hall, Diakoniestr. 10, 74523, Schwäbisch Hall, Deutschland
| | - Z Zielska
- Klinik für Allgemein- und Viszeralchirurgie, Das DIAK, Diakonieklinikum Schwäbisch Hall, Diakoniestr. 10, 74523, Schwäbisch Hall, Deutschland
| | - K Maurer
- Aesculap AG, Tuttlingen, Deutschland
| | - P Baumann
- Aesculap AG, Tuttlingen, Deutschland
| |
Collapse
|
41
|
Breitung B, Baumann P, Sommer H, Janek J, Brezesinski T. In situ and operando atomic force microscopy of high-capacity nano-silicon based electrodes for lithium-ion batteries. Nanoscale 2016; 8:14048-14056. [PMID: 27222212 DOI: 10.1039/c6nr03575b] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Silicon is a promising next-generation anode material for high-energy-density lithium-ion batteries. While the alloying of nano- and micron size silicon with lithium is relatively well understood, the knowledge of mechanical degradation and structural rearrangements in practical silicon-based electrodes during operation is limited. Here, we demonstrate, for the first time, in situ and operando atomic force microscopy (AFM) of nano-silicon anodes containing polymer binder and carbon black additive. With the help of this technique, the surface topography is analyzed while electrochemical reactions are occurring. In particular, changes in particle size as well as electrode structure and height are visualized with high resolution. Furthermore, the formation and evolution of the solid-electrolyte interphase (SEI) can be followed and its thickness determined by phase imaging and nano-indentation, respectively. Major changes occur in the first lithiation cycle at potentials below 0.6 V with respect to Li/Li(+) due to increased SEI formation - which is a dynamic process - and alloying reactions. Overall, these results provide insight into the function of silicon-based composite electrodes and further show that AFM is a powerful technique that can be applied to important battery materials, without restriction to thin film geometries.
Collapse
Affiliation(s)
- Ben Breitung
- Battery and Electrochemistry Laboratory, Institute of Nanotechnology, Karlsruhe Institute of Technology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany.
| | | | | | | | | |
Collapse
|
42
|
Kaivorinne AL, Lintunen J, Baumann P. Fulminant neuromyelitis optica in a Finnish woman - a case report. Clin Case Rep 2016; 4:782-5. [PMID: 27525084 PMCID: PMC4974428 DOI: 10.1002/ccr3.624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2016] [Revised: 05/08/2016] [Accepted: 05/28/2016] [Indexed: 11/11/2022] Open
Abstract
Neuromyelitis optica is a rare inflammatory, demyelinating disease of the central nervous system that predominantly targets the optic nerves and spinal cord. Our case represents an unusual and severe course of neuromyelitis optica. Despite several forms of treatment, our patient died after a severe and short‐term attack.
Collapse
Affiliation(s)
- Anna-Lotta Kaivorinne
- Department of Neurology; Lapland Hospital District; Lapland Central Hospital; Rovaniemi Finland
| | - Janne Lintunen
- Department of Neurology; Lapland Hospital District; Lapland Central Hospital; Rovaniemi Finland
| | - Peter Baumann
- Department of Neurology; Lapland Hospital District; Lapland Central Hospital; Rovaniemi Finland
| |
Collapse
|
43
|
Diakaki M, Audouin L, Berthoumieux E, Calviani M, Colonna N, Dupont E, Duran I, Gunsing F, Leal-Cidoncha E, Le Naour C, Leong L, Mastromarco M, Paradela C, Tarrio D, Tassan-Got L, Aerts G, Altstadt S, Alvarez H, Alvarez-Velarde F, Andriamonje S, Andrzejewski J, Badurek G, Barbagallo M, Baumann P, Becares V, Becvar F, Belloni F, Berthier B, Billowes J, Boccone V, Bosnar D, Brugger M, Calvino F, Cano-Ott D, Capote R, Carrapiço C, Cennini P, Cerutti F, Chiaveri E, Chin M, Cortes G, Cortes-Giraldo M, Cosentino L, Couture A, Cox J, David S, Dillmann I, Domingo-Pardo C, Dressler R, Dridi W, Eleftheriadis C, Embid-Segura M, Ferrant L, Ferrari A, Finocchiaro P, Fraval K, Fujii K, Furman W, Ganesan S, Garcia A, Giubrone G, Gomez-Hornillos M, Goncalves I, Gonzalez-Romero E, Goverdovski A, Gramegna F, Griesmayer E, Guerrero C, Gurusamy P, Haight R, Heil M, Heinitz S, Igashira M, Isaev S, Jenkins D, Jericha E, Kadi Y, Kaeppeler F, Karadimos D, Karamanis D, Kerveno M, Ketlerov V, Kivel N, Kokkoris M, Konovalov V, Krticka M, Kroll J, Lampoudis C, Langer C, Lederer C, Leeb H, Lo Meo S, Losito R, Lozano M, Manousos A, Marganiec J, Martinez T, Marrone S, Massimi C, Mastinu P, Mendoza E, Mengoni A, Milazzo P, Mingrone F, Mirea M, Mondelaers W, Moreau C, Mosconi M, Musumarra A, O’Brien S, Pancin J, Patronis N, Pavlik A, Pavlopoulos P, Perkowski J, Perrot L, Pigni M, Plag R, Plompen A, Plukis L, Poch A, Pretel C, Praena J, Quesada J, Rauscher T, Reifarth R, Riego A, Roman F, Rudolf G, Rubbia C, Rullhusen P, Salgado J, Santos C, Sarchiapone L, Sarmento R, Saxena A, Schillebeeckx P, Schmidt S, Schumann D, Stephan C, Tagliente G, Tain J, Tavora L, Terlizzi R, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Versaci R, Vermeulen M, Villamarin D, Vincente M, Vlachoudis V, Vlastou R, Voss F, Wallner A, Walter S, Ware T, Weigand M, Weiß C, Wiesher M, Wisshak K, Wright T, Zugec P. Towards the high-accuracy determination of the238U fission cross section at the threshold region at CERN – n_TOF. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611102002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Paradela C, Duran I, Tassan-Got L, Audouin L, Berthier B, Isaev S, Le Naour C, Stephan C, Tarrío D, Abbondanno U, Aerts G, Álvarez-Pol H, Álvarez-Velarde F, Andriamonje S, Andrzejewski J, Badurek G, Baumann P, Becvar F, Berthoumieux E, Calviño F, Calviani M, Cano-Ott D, Capote R, Carrapiço C, Cennini P, Chepel V, Chiaveri E, Colonna N, Cortes G, Couture A, Cox J, Dahlfors M, David S, Dillmann I, Domingo-Pardo C, Dridi W, Eleftheriadis C, Embid-Segura M, Ferrant L, Ferrari A, Ferreira-Marques R, Fujii K, Furman W, Gonçalves I, Gonzalez-Romero E, Goverdovski A, Gramegna F, Guerrero C, Gunsing F, Haight R, Heil M, Igashira M, Jericha E, Kadi Y, Kaeppeler F, Karadimos D, Kerveno M, Ketlerov V, Koehler P, Konovalov V, Krticka M, Lampoudis C, Lederer C, Leeb H, Lindote A, Lukic S, Marganiec J, Martinez T, Marrone S, Massimi C, Mastinu P, Mengoni A, Milazzo P, Moreau C, Mosconi M, Pancin SJ, Pavlik A, Pavlopoulos P, Perrot L, Plag R, Plompen A, Plukis A, Poch A, Pretel C, Praena J, Quesada J, Rauscher T, Reifarth R, Rubbia C, Rudolf G, Rullhusen P, Salgado J, Santos C, Sarchiapone L, Savvidis I, Tagliente G, Tain J, Tavora L, Terlizzi R, Vaz P, Ventura A, Villamarin D, Vincente M, Vlachoudis V, Vlastou R, Voss F, Walter S, Weiss C, Wiesher M, Wisshak K. High accuracy235U(n,f) data in the resonance energy region. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611102003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Baumann P, Greil W. Clinical pharmacological management of polypharmacy in old age depression. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Polypharmacy is the rule in psychogeriatric patients, as they present frequently comorbidities such as depression, dementia [often including Behavioral and Psychological Symptoms of Dementia (BPSD)] and somatic diseases. Recommended treatments for geriatric depression are antidepressant medications, psychotherapy and psychosocial interventions [1]. Besides antidepressants, other psychotropic drugs are often co-prescribed, but somatic drugs are also needed for the treatment of other concomitant diseases. This situation increases the risk for adverse effects due to pharmacokinetic and pharmacodynamic interactions, especially since the organism of elderly patients displays a lowered homeostatic reserve and a decrease of functions, which allows resisting to xenobiotic influences.On the other hand, there are also studies which suggest that in hospitalized psychogeriatric patients, the incidence of severe adverse reactions is lower in patients > 60 y than in those < 60 y [2]. This is one of the results of the AMSP-study group, which in German speaking countries has developed a pharmacovigilance program in psychiatric hospitals.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
46
|
Tseng CK, Wang HF, Burns A, Schroeder M, Gaspari M, Baumann P. Human Telomerase RNA Processing and Quality Control. Cell Rep 2015; 13:2232-43. [DOI: 10.1016/j.celrep.2015.10.075] [Citation(s) in RCA: 104] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Revised: 10/02/2015] [Accepted: 10/27/2015] [Indexed: 12/11/2022] Open
|
47
|
Frazier M, Ackerman L, Baumann P, Potter D, Yoshida M. Wh-filler-gap dependency formation guides reflexive antecedent search. Front Psychol 2015; 6:1504. [PMID: 26500579 PMCID: PMC4599314 DOI: 10.3389/fpsyg.2015.01504] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 09/17/2015] [Indexed: 11/17/2022] Open
Abstract
Prior studies on online sentence processing have shown that the parser can resolve non-local dependencies rapidly and accurately. This study investigates the interaction between the processing of two such non-local dependencies: wh-filler-gap dependencies (WhFGD) and reflexive-antecedent dependencies. We show that reflexive-antecedent dependency resolution is sensitive to the presence of a WhFGD, and argue that the filler-gap dependency established by WhFGD resolution is selected online as the antecedent of a reflexive dependency. We investigate the processing of constructions like (1), where two NPs might be possible antecedents for the reflexive, namely which cowgirl and Mary. Even though Mary is linearly closer to the reflexive, the only grammatically licit antecedent for the reflexive is the more distant wh-NP, which cowgirl. (1). Which cowgirl did Mary expect to have injured herself due to negligence? Four eye-tracking text-reading experiments were conducted on examples like (1), differing in whether the embedded clause was non-finite (1 and 3) or finite (2 and 4), and in whether the tail of the wh-dependency intervened between the reflexive and its closest overt antecedent (1 and 2) or the wh-dependency was associated with a position earlier in the sentence (3 and 4). The results of Experiments 1 and 2 indicate the parser accesses the result of WhFGD formation during reflexive antecedent search. The resolution of a wh-dependency alters the representation that reflexive antecedent search operates over, allowing the grammatical but linearly distant antecedent to be accessed rapidly. In the absence of a long-distance WhFGD (Experiments 3 and 4), wh-NPs were not found to impact reading times of the reflexive, indicating that the parser's ability to select distant wh-NPs as reflexive antecedents crucially involves syntactic structure.
Collapse
Affiliation(s)
- Michael Frazier
- Department of Linguistics, Northwestern University Evanston, IL, USA
| | - Lauren Ackerman
- Department of Linguistics, Northwestern University Evanston, IL, USA
| | - Peter Baumann
- Department of Linguistics, Northwestern University Evanston, IL, USA
| | - David Potter
- Department of Linguistics, Northwestern University Evanston, IL, USA
| | - Masaya Yoshida
- Department of Linguistics, Northwestern University Evanston, IL, USA
| |
Collapse
|
48
|
|
49
|
Kauranen T, Laari S, Turunen K, Melkas M, Mustanoja S, Baumann P, Poutiainen E. Use of Stroke-Related Income Supplements and Predictors of Use in a Working-Aged Finnish Ischemic Stroke Cohort. J Stroke Cerebrovasc Dis 2015; 24:1715-23. [DOI: 10.1016/j.jstrokecerebrovasdis.2015.03.049] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 02/25/2015] [Accepted: 03/08/2015] [Indexed: 11/28/2022] Open
|
50
|
Abstract
Earth-Science data are composite, multi-dimensional and of significant size, and as such, continue to pose a number of ongoing problems regarding their management. With new and diverse information sources emerging as well as rates of generated data continuously increasing, a persistent challenge becomes more pressing: To make the information existing in multiple heterogeneous resources readily available. The widespread use of the XML data-exchange format has enabled the rapid accumulation of semi-structured metadata for Earth-Science data. In this paper, we exploit this popular use of XML and present the means for querying metadata emanating from multiple sources in a succinct and effective way. Thereby, we release the user from the very tedious and time consuming task of examining individual XML descriptions one by one. Our approach, termed Meta-Array Data Search (MAD Search), brings together diverse data sources while enhancing the user-friendliness of the underlying information sources. We gather metadata using different standards and construct an amalgamated service with the help of tools that discover and harvest such metadata; this service facilitates the end-user by offering easy and timely access to all metadata. The main contribution of our work is a novel query language termed xWCPS, that builds on top of two widely-adopted standards: XQuery and the Web Coverage Processing Service (WCPS). xWCPS furnishes a rich set of features regarding the way scientific data can be queried with. Our proposed unified language allows for requesting metadata while also giving processing directives. Consequently, the xWCPS-enabled MAD Search helps in both retrieval and processing of large data sets hosted in an heterogeneous infrastructure. We demonstrate the effectiveness of our approach through diverse use-cases that provide insights into the syntactic power and overall expressiveness of xWCPS. We evaluate MAD Search in a distributed environment that comprises five high-volume array-databases whose sizes range between 20 and 100 GB and so, we ascertain the applicability and potential of our proposal.
Collapse
Affiliation(s)
| | | | | | | | - Yannis Ioannidis
- Athena Research and Innovation Center, 15125 Maroussi, Greece
- University of Athens, 15784 Athens, Greece
| | - Alex Delis
- Athena Research and Innovation Center, 15125 Maroussi, Greece
- University of Athens, 15784 Athens, Greece
| |
Collapse
|